Market Overview

UPDATE: Stifel Nicolaus Initiates Edwards Lifesciences at Buy on Growth Outlook

Share:
Related EW
Mid-Afternoon Market Update: Fang Holdings Drops Following Q3 Results; Recro Pharma Shares Surge
Mid-Day Market Update: Crude Oil Up Over 2%; PhaseRx Shares Spike Higher
Weekly Top Insider Buys Highlight for the Week of Dec. — (GuruFocus)

Stifel Nicolaus initiated coverage on Edwards Lifesciences (NYSE: EW) with a Buy rating and a $113 price target.

Stifel Nicolaus noted, "We are initiating coverage of Edwards Lifesciences Corp. (EW) shares with a Buy rating and a $113 12-month target price. Over time, we think that Edwards' current market leading TAVR share (approximately 64% WW), its healthy new product pipeline, and the move into new geographies (e.g.Japan) will substantially expand the company's profitability and drive sustained above-industry-average growth through mid-decade. As the Transcatheter Valve Replacement market evolves further in years ahead, we believe Edwards is poised to benefit, driving significant top-line growth and operating leverage."

Edwards Lifesciences closed at $85.74 on Monday.

Latest Ratings for EW

DateFirmActionFromTo
Nov 2016Northland SecuritiesUpgradesMarket PerformOutperform
Jul 2016JMP SecuritiesMaintainsMarket Outperform
Jul 2016Bank of AmericaUpgradesNeutralBuy

View More Analyst Ratings for EW
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (EW)

View Comments and Join the Discussion!